ACADIA Pharmaceuticals Inc ACAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACAD is a good fit for your portfolio.
News
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
-
Acadia Pharma's stock falls 15% after failed drug trial
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
-
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
-
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Trading Information
- Previous Close Price
- $18.20
- Day Range
- $18.05–18.50
- 52-Week Range
- $17.56–33.99
- Bid/Ask
- $18.05 / $18.50
- Market Cap
- $3.05 Bil
- Volume/Avg
- 1.5 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 598
- Website
- https://www.acadia.com
Comparables
Valuation
Metric
|
ACAD
|
ITCI
|
VNDA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 52.93 |
Price/Book Value | 6.94 | 11.36 | 0.41 |
Price/Sales | 4.10 | 14.46 | 1.16 |
Price/Cash Flow | — | — | 16.53 |
Price/Earnings
ACAD
ITCI
VNDA
Financial Strength
Metric
|
ACAD
|
ITCI
|
VNDA
|
---|---|---|---|
Quick Ratio | 2.13 | 4.95 | 4.82 |
Current Ratio | 2.42 | 5.41 | 4.94 |
Interest Coverage | — | — | — |
Quick Ratio
ACAD
ITCI
VNDA
Profitability
Metric
|
ACAD
|
ITCI
|
VNDA
|
---|---|---|---|
Return on Assets (Normalized) | −1.90% | −13.47% | 2.20% |
Return on Equity (Normalized) | −3.17% | −15.88% | 2.62% |
Return on Invested Capital (Normalized) | −5.76% | −17.96% | 2.57% |
Return on Assets
ACAD
ITCI
VNDA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xcmryjpdxb | Wqvzy | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hkqkgstn | Nhydfb | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xwrsrfwx | Gmzmt | $106.1 Bil | |
MRNA
| Moderna Inc | Lsgypym | Wjd | $42.3 Bil | |
ARGX
| argenx SE ADR | Vphhknswl | Wkzw | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Vcjvpchq | Nzjz | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ctwjphv | Djqyxv | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jqdtyhzz | Wscwbsr | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Znhtpcwhf | Vqgpzf | $13.6 Bil | |
INCY
| Incyte Corp | Drkzgbncj | Zwxvgqp | $12.8 Bil |